Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	37.41	86.59	124.33	65.4	193.99	295.18
Cash & Short-Term Investments	37.41	86.59	124.33	65.4	193.99	295.18
Cash Growth	-60.02%	-30.36%	90.10%	-66.29%	-34.28%	21.40%
Accounts Receivable	12.29	6.74	16.85	-	1.34	-
Other Receivables	9.21	34.83	76.01	71.18	46.12	108.3
Receivables	21.5	41.57	92.87	71.18	47.46	108.3
Inventory	149.4	194.27	246.9	106.86	50.26	-
Prepaid Expenses	76.86	1.54	8.07	16.89	13	2.31
Other Current Assets	0.18	51.17	133.73	201.37	208.81	155.21
Total Current Assets	285.35	375.13	605.9	461.69	513.52	561.01
Property, Plant & Equipment	5.24	0.04	64.9	88.2	71.05	73.8
Long-Term Deferred Charges	-	296.46	167.69	99.67	102	49.67
Other Long-Term Assets	-0	-	3.95	3.95	3.95	3.95
Total Assets	618.36	671.62	842.43	653.51	690.52	688.43

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	19.15	8.96	242.57	30.97	23.3	41.39
Accrued Expenses	6.68	12.71	41.19	140.89	66.48	65.76
Current Portion of Long-Term Debt	58.7	-	82.5	62.5	-	-
Current Portion of Leases	3.04	-	13.27	13.37	9.16	7.91
Current Unearned Revenue	-	23.48	147.26	75.41	136.06	95.39
Other Current Liabilities	1.46	7.52	11.15	3.42	1.56	9.22
Total Current Liabilities	89.03	52.66	537.94	326.56	236.57	219.67
Long-Term Debt	-	58.31	66.37	112.9	-	-
Long-Term Leases	2.18	-	29.58	42.71	29.06	36.48
Long-Term Unearned Revenue	-	-	-	-	-	0.54
Other Long-Term Liabilities	-	-	-0	0.01	-	-
Total Liabilities	91.21	110.97	633.89	482.17	265.63	256.69

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2.06	2.06	343.5	6.68	6.17	5.61
Additional Paid-In Capital	1,389	1,386	1,395	1,429	1,294	1,134
Retained Earnings	-873.81	-837.61	-1,540	-1,274	-885.83	-713.31
Comprehensive Income & Other	10.16	10.11	10.23	10.12	10.32	5.16
Shareholders' Equity	527.15	560.65	208.54	171.34	424.89	431.74
Total Liabilities & Equity	618.36	671.62	842.43	653.51	690.52	688.43

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	63.93	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt)	-26.52	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share	-1.29	1.72	-6.85	-723.19	761.51	1328.76
Filing Date Shares Outstanding	20.61	20.61	12.24	0.24	0.22	0.2
Total Common Shares Outstanding	20.61	20.61	12.24	0.24	0.22	0.2
Working Capital	196.33	322.47	67.96	135.14	276.96	341.34
Book Value Per Share	25.58	27.21	17.04	718.44	1930.89	2155.27
Tangible Book Value	199.38	560.65	208.54	171.34	424.89	431.74
Tangible Book Value Per Share	9.68	27.21	17.04	718.44	1930.89	2155.27
Machinery	-	2.75	62.43	61.93	-	43.49

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error